OptimizeRx (OPRX)
(Delayed Data from NSDQ)
$12.50 USD
-0.12 (-0.95%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $12.48 -0.02 (-0.16%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth D Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
OPRX 12.50 -0.12(-0.95%)
Will OPRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OPRX
Best Growth Stocks to Buy for August 1st
Bull Of The Day: OptimizeRX (OPRX)
OPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does OptimizeRx Have a Moat in the Crowded HealthTech Space?
Blackbaud (BLKB) Q2 Earnings and Revenues Surpass Estimates
Take the Zacks Approach to Beat the Markets: AngloGold Ashanti, Caterpillar & Hershey in Focus
Other News for OPRX
Paynela Appoints Healthcare Technology Veteran William Febbo to Board of Directors | OPRX Stock News
OptimizeRx Corp (OPRX) Stock Price Down 3.9% on Jul 18
OptimizeRx: Stock Could Rise As Profitability Is Achieved
OptimizeRx Sets Second Quarter 2025 Conference Call for August 7, 2025, at 4:30 p.m. ...
OptimizeRx Corp (OPRX) Trading 8.48% Higher on Jul 16